Cover Image
市場調查報告書

甲狀腺未分化癌症:開發平台分析

Anaplastic Thyroid Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251531
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
甲狀腺未分化癌症:開發平台分析 Anaplastic Thyroid Cancer - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 73 Pages
簡介

所謂甲狀腺未分化癌症是指甲狀腺的濾胞表皮上產生的未分化腫瘤。主要的症狀有咳嗽和咯血,吞嚥障礙,呼吸聲音大,嘶啞聲,嗓音改變等。易罹病素質包含了甲狀腺瘤·甲狀腺結節·甲狀腺炎的病歷,及甲狀腺疾病的家族病史,女性·亞洲人種等。主要的治療方法有外科手術和化療,放射治療等。

本報告提供全球各國治療甲狀腺未分化癌症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

甲狀腺未分化癌症概要

治療藥的開發

  • 甲狀腺未分化癌症開發中產品:概要
  • 甲狀腺未分化癌症開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • 第一三共
  • Exelixis, Inc.
  • Genelux Corporation
  • GlaxoSmithKline Plc
  • Immune Pharmaceuticals Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Plexxikon Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (dabrafenib mesylate + trametinib dimethyl sulfoxide)
  • cabozantinib s-malate
  • ceritinib
  • CLM-3
  • CLM-94
  • crolibulin
  • efatutazone
  • GLONC-2
  • PLX-3397
  • PLX-8394
  • sapanisertib

最新開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8246IDB

Summary

Global Markets Direct's, 'Anaplastic Thyroid Cancer - Pipeline Review, H2 2016', provides an overview of the Anaplastic Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
  • The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anaplastic Thyroid Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Anaplastic Thyroid Cancer - Overview
    • Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis
  • Anaplastic Thyroid Cancer - Therapeutics under Development by Companies
  • Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
  • Anaplastic Thyroid Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Anaplastic Thyroid Cancer - Products under Development by Companies
  • Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes
  • Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development
    • Daiichi Sankyo Company, Limited
    • Genelux Corporation
    • Immune Pharmaceuticals Inc.
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • Pfizer Inc.
    • Plexxikon Inc.
    • Trophogen, Inc.
  • Anaplastic Thyroid Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ceritinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLM-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crolibulin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • efatutazone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLONC-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GLV-1h153 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexidartinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-8394 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • utomilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anaplastic Thyroid Cancer - Dormant Projects
  • Anaplastic Thyroid Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016
  • Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H2 2016
  • Anaplastic Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Anaplastic Thyroid Cancer - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Anaplastic Thyroid Cancer, H2 2016
  • Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top